The Union for International Cancer Control and the World Health Organization have both chosen to prioritize generic and biosimilar cancer drugs in their efforts to improve access to treatment across low- to middle-income countries, rather than focusing on new technologies like immunotherapy.
Speaking at the World Cancer Congress 2022 last month, UICC CEO Gary Adams explained that the organization is engaging with generic and biosimilar medicine producers to find ways of increasing supply of their medicines to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?